Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Homoserine Lactone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Homoserine Lactone SCHEMBL1536657 | 1.00 | — | — | |
| Homoserine Lactone SCHEMBL1034274 | 1.00 | — | — | |
| Homoserine Lactone SCHEMBL79968 | 0.97 | — | — | |
| Homoserine Lactone SCHEMBL79466 | 0.97 | — | — | |
| Homoserine Lactone SCHEMBL79969 | 0.97 | — | — | |
| SCHEMBL731550 | 0.97 | TSHR (0.32) | — | |
| Homoserine Lactone SCHEMBL1402931 | 0.95 | — | — | |
| Homoserine Lactone SCHEMBL1147212 | 0.95 | — | — | |
| Homoserine Lactone SCHEMBL787339 | 0.95 | — | — | |
| Homoserine Lactone SCHEMBL15227619 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077373-B1 | PREPARATION OF COBICISTAT INTERMEDIATES | MYLAN LABORATORIES LTD (IN) | 2018-09-12 | — | — | EP | disclosed |
| US-9975864-B2 | Preparation of cobicistat intermediates | MYLAN LABORATORIES LIMITED (IN) | 2018-05-22 | — | — | US | disclosed |
| US-20160297780-A1 | Preparation of Cobicistat Intermediates | Mylan Laboratories Ltd. (IN) | 2016-10-13 | — | — | US | disclosed |
| US-6525056-B2 | A fused nitrogen containing heterocyclic compound useful for treating psychiatric and neurological disorders, anxiety, post-traumatic stress, supranuclear palsy, feeding, immunological, cardiovascular and hypersensitivity disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6448261-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS; TREATING ANXIETY, DEPRESSION, AND OTHER PSYCHIATRIC AND NEUROLOGICAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-1012151-B1 | HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-0935601-A4 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | DU PONT PHARM CO (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20010025042-A1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-09-27 | — | — | US | disclosed |
| US-6107300-A | CORTICOTROPIN RELEASING FACTOR ANTAGONIST; PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0935601-A2 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | Du Pont Pharmaceuticals Company (US) | 1999-08-18 | — | — | EP | disclosed |
| WO-1997035539-A2 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | DU PONT PHARMACEUTICALS COMPANY (US) | 1997-10-02 | — | — | WO | disclosed |